Holmusk Announces Closing of US$21.5 Million Series A Funding Round, Led by Optum Ventures & Health Catalyst Capital
Holmusk Announces Closing of US$21.5 Million Series A Funding Round, Led by Optum Ventures & Health Catalyst Capital
05/18/20, 4:03 AM
Location
Money raised
$21 million
Industry
data and analytics
mobile
software
health care
information technology
Round Type
series a
Holmusk, a leading data science and health technology company, today announced a US$21.5 million funding round. The round was led by Optum Ventures (OV) and Health Catalyst Capital (HCC) and included existing investors Heritas Capital and other individuals.
Company Info
Location
new york, united states
Additional Info
Holmusk is on a mission to reinvent behavioral health and transform lives with Real-World Evidence and digital innovation. Headquartered in Singapore and New York, Holmusk generates evidence and builds digital solutions to advance behavioral health research, innovation, and care.
NeuroBlu, Holmusk's flagship product, synthesizes Real-World Data (RWD) with seamless analytic tools, enabling users to create actionable insights that drive behavioral health transformation. NeuroBlu is powered by an industry-leading and continually growing behavioral health clinical dataset, with over 20 years of data on over half a million patients and 20+ million encounters. Holmusk uses advanced proprietary analytics to enrich the data, with Natural Language Processing and predictive disease models designed specifically for behavioral health. Holmusk augments its data and analytic offerings with powerful digital solutions that enhance patient engagement, support disease self-management, and capture patient-reported outcomes to help guide clinical decisions and analytics. For more information, please visit www.holmusk.com.